A detailed history of Fin Trust Capital Advisors, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Fin Trust Capital Advisors, LLC holds 140 shares of VRTX stock, worth $64,639. This represents 0.01% of its overall portfolio holdings.

Number of Shares
140
Previous 140 -0.0%
Holding current value
$64,639
Previous $65,000 -0.0%
% of portfolio
0.01%
Previous 0.01%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 24, 2024

BUY
$392.81 - $485.53 $6,284 - $7,768
16 Added 12.9%
140 $65,000
Q4 2023

Feb 13, 2024

BUY
$343.0 - $410.68 $3,430 - $4,106
10 Added 8.77%
124 $50,000
Q3 2023

Oct 24, 2023

SELL
$338.18 - $362.46 $54,108 - $57,993
-160 Reduced 58.39%
114 $39,000
Q4 2022

Feb 14, 2023

SELL
$285.76 - $321.48 $285,760 - $321,480
-1,000 Reduced 78.49%
274 $79,000
Q3 2022

Oct 20, 2022

BUY
$273.83 - $305.53 $348,859 - $389,245
1,274 New
1,274 $371,000
Q3 2021

Nov 16, 2021

SELL
$181.39 - $202.99 $9,069 - $10,149
-50 Closed
0 $0
Q2 2021

Aug 16, 2021

SELL
$187.49 - $221.1 $1,687 - $1,989
-9 Reduced 15.25%
50 $10,000
Q4 2020

Feb 16, 2021

SELL
$207.01 - $276.09 $54,650 - $72,887
-264 Reduced 81.73%
59 $14,000
Q3 2020

Nov 10, 2020

BUY
$255.65 - $303.1 $2,556 - $3,031
10 Added 3.19%
323 $88,000
Q2 2020

Sep 11, 2020

BUY
$225.48 - $295.8 $70,575 - $92,585
313 New
313 $91,000
Q2 2020

Aug 14, 2020

SELL
$225.48 - $295.8 $75,986 - $99,684
-337 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$199.77 - $247.81 $3,196 - $3,964
16 Added 4.98%
337 $80,000
Q4 2019

Jan 23, 2020

SELL
$166.71 - $223.91 $4,501 - $6,045
-27 Reduced 7.76%
321 $70,000
Q2 2019

Aug 01, 2019

SELL
$164.61 - $190.37 $3,950 - $4,568
-24 Reduced 6.45%
348 $63,000
Q1 2019

May 09, 2019

SELL
$163.73 - $194.7 $4,911 - $5,841
-30 Reduced 7.46%
372 $68,000
Q4 2018

Feb 11, 2019

BUY
$151.91 - $192.21 $61,067 - $77,268
402 New
402 $67,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $119B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Fin Trust Capital Advisors, LLC Portfolio

Follow Fin Trust Capital Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fin Trust Capital Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fin Trust Capital Advisors, LLC with notifications on news.